Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Verona Pharma

NASDAQ VRNA
$106.69 0.30 0.28%
Today share price
UK
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 31.25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
5.39B
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
5.23B
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.42
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
84.93M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
129.74 %

Upcoming events Verona Pharma

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Verona Pharma

Stock analysis Verona Pharma

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-32.87 -1.50
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
18.51 1.38
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-49.41 -0.54
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.50 0.35
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-72.39 -27.86

Price change Verona Pharma per year

28.71$ 106.69$
Min Max

Summary analysis Verona Pharma

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Verona Pharma

Revenue and net income Verona Pharma

All parameters

About company Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Address:
3 More London Riverside, London, United Kingdom, SE1 2RE
Company name: Verona Pharma
Issuer ticker: VRNA
ISIN: US9250501064
Country: UK
Exchange: NASDAQ
Currency: $
IPO date: 2017-04-27
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.veronapharma.com